The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder

被引：8
|
作者：
Florea, I. [1 ]
Dragheim, M. [1 ]
Loft, H. [2 ]
机构：
[1] H Lundbeck & Co AS, Mood & Anxiety Disorders, Copenhagen, Denmark
[2] H Lundbeck & Co AS, Biometr, Copenhagen, Denmark
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2012年 / 22卷
关键词：
D O I：
10.1016/S0924-977X(12)70383-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S255 / S256
页数：2
相关论文
共 50 条
  • [31] A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
    Richards, Cynthia
    Iosifescu, Dan V.
    Mago, Rajnish
    Sarkis, Elias
    Geibel, Brooke
    Dauphin, Matthew
    McIntyre, Roger S.
    Weisler, Richard
    Brawman-Mintzer, Olga
    Gu, Joan
    Madhoo, Manisha
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2018, 38 (04) : 336 - 343
  • [32] A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder
    Henigsberg, Neven
    Mahableshwarkar, Atul R.
    Jacobsen, Paula
    Chen, Yinzhong
    Thase, Michael E.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (07) : 953 - 959
  • [33] Vortioxetine (Lu AA21004) disinhibits pyramidal cell output and enhances theta rhythms and long-term plasticity in the hippocampus
    Dale, E.
    Zhang, H.
    Leiser, S. C.
    Chao, Y.
    Yang, C.
    Plath, N.
    Sanchez, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S394 - S394
  • [34] Duloxetine in the treatment of major depressive disorder: an open-label study
    James I Hudson
    David G Perahia
    Inmaculada Gilaberte
    Fujun Wang
    John G Watkin
    Michael J Detke
    BMC Psychiatry, 7
  • [35] Duloxetine in the treatment of major depressive disorder: an open-label study
    Hudson, James I.
    Perahia, David G.
    Gilaberte, Inmaculada
    Wang, Fujun
    Watkin, John G.
    Detke, Michael J.
    BMC PSYCHIATRY, 2007, 7 (1) : 43
  • [36] MAJOR DEPRESSIVE DISORDER, ANHEDONIA, AND AGOMELATINE: AN OPEN-LABEL STUDY
    Martinotti, G.
    Di Iorio, G.
    Guglielmo, R.
    De Berardis, D.
    Janiri, L.
    Di Giannantonio, M.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [37] MAJOR DEPRESSIVE DISORDER, ANHEDONIA AND AGOMELATINE: AN OPEN-LABEL STUDY
    di Giannantonio, M.
    Di Iorio, G.
    Guglielmo, R.
    De Berardis, D.
    Conti, C. M.
    Acciavatti, T.
    Cornelio, M.
    Martinotti, G.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2011, 25 (01): : 109 - 114
  • [38] Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder
    Emslie, Graham J.
    Yeung, Paul P.
    Kunz, Nadia R.
    CNS SPECTRUMS, 2007, 12 (03) : 223 - 233
  • [39] Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder
    Andersen, SW
    Clemow, DB
    Corya, SA
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (11) : 1468 - 1476
  • [40] The safety and tolerability of vortioxetine in treating adults with major depressive disorder after 52 weeks of open-label treatment
    Baldwin, D. S.
    Mahableshwarkar, A. R.
    Chrones, L.
    Palo, W.
    Matz, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S464 - S464
12345